Join to View Full Profile
4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192
Dr. Oppelt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2008 - 2012
University of Missouri-Columbia School of MedicineClass of 2008
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2015 - 2026
OH State Medical License 2008 - 2016
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancer.Patrick M Grierson, Crystal Wolf, Rama Suresh, Andrea Wang-Gillam, Benjamin R Tan
Clinical Cancer Research. 2025-03-24 - Long-Term Outcomes After Elective Contralateral Neck Dissection for HPV-Related Oropharyngeal Cancer.Ray Y Wang, Molly E Heft Neal, Wade L Thorstad, Hiram A Gay, Anthony J Apicelli
Otolaryngology--Head and Neck Surgery. 2025-03-19 - Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial.Peter J Oppelt, Sidharth V Puram, Jingxia Liu, Jessica C Ley, Douglas Adkins
Cancers. 2025-01-27
Journal Articles
- Outcomes of Patients with Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated with Transoral SurgeryPeter Oppelt, Kevin Palka, JAMA Otolaryngology–Head & Neck Surgery
Press Mentions
- Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
